Inovio Pharmaceuticals (AMEX:INO) announced Tuesday chairman of its scientific advisory board David Weiner was elected as a fellow by the American Association for the Advancement of Science.
The fellowship is based on scientifically or socially distinguished
efforts to advance science or its applications. Members are elected to
the organization by their peers.
The world’s largest general scientific society is a non-profit
organization and devoted to advancing science around the world by
serving as educator, spokesperson and professional association. It has
been electing scientists to its society since 1874.
In addition to organizing membership activities, the organization
publishes the journal Science, as well as a number of scientific
newsletters, books and reports, and spearheads programs that raise the
bar for understanding science worldwide.
Weiner, often dubbed the “father of synthetic DNA vaccines,” said
Inovio, is being honoured for his pioneering and enabling discoveries in
the area of synthetic DNA vaccines and promoting the nascent field of
research during its early stages.
He was recognized at the Fellows Forum, which was held February 18
during the American Association's annual meeting in Vancouver.
In the early 1990s, Weiner’s laboratory helped found the field of
synthetic DNA vaccines, and had been responsible for the first synthetic
DNA vaccine investigational new drug application.
"This award is further recognition of David's visionary and untiring
efforts at his lab in the University of Pennsylvania," chief executive
Joseph Kim said in a prepared statement.
"These efforts led to the first discovery in the field of synthetic
DNA vaccines. He created the scientific foundation for Inovio's clinical
stage pipeline of synthetic vaccines for cancer, HIV, influenza and
many other infectious diseases."
Inovio Pharmaceuticals, formerly Inovio Biomedical Corp., is developing DNA-based vaccines, to treat and prevent cancers and infectious diseases.
Its SynCon vaccines are designed to provide broad cross-strain
protection against known as well as newly emergent unmatched strains of
pathogens such as influenza.
These synthetic vaccines, in combination with Inovio's proprietary
electroporation delivery, have been shown to generate positive immune
responses, along with a favourable safety profile.
Inovio's clinical programs include phase II studies for cervical
dysplasia, pre-cancerous lesions, leukemia and the hepatitis C virus, as
well as phase I studies for influenza and HIV.